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Abstract
OBJECTIVE: To evaluate the therapeutic effects of
low-frequency phonophoresis with a Chinese herb-
al medicine (CHM) compared with sodium diclofe-
nac (SD) for knee osteoarthritis (KOA).
METHODS: In this double-blind, randomized, pla-
cebo-controlled trial, 100 KOA patients were as-
signed randomly to a placebo group, a CHM group,
or SD group. Low-frequency phonophoresis was
used to improve the efficiency of drug delivery.
Pain at rest [using a visual analog scale (VAS)], pain
on movement (VAS), and range of motion (de-
grees) in the three groups were evaluated using
the Western Ontario and McMaster Universities Os-
teoarthritis Index (WOMACAI) scores. Safety assess-
ments comprised emergency adverse events, as
well as laboratory tests of blood biochemistry, cre-
atinine, blood urea nitrogen, alanine aminotransfer-
ase and aspartate aminotransferase.
RESULTS: Significant improvements were found af-
ter treatment in all outcome measures except stiff-
ness and range of motion in patients in the CHMP
group and SDP group (P < 0.05). No significant dif-
ferences in all outcome measures were found be-
tween the CHMP group and SDP group.
CONCLUSION: CHMP and SDP can show good ther-
apeutic effects for KOA in terms of relieving pain
and improving physical function.
© 2016 JTCM. All rights reserved.
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INTRODUCTION
Osteoarthritis (OA) is a degenerative disease character-
ized by: chronic pain and stiffness in joints; joint defor-
mity; articular instability; reduction in the range of mo-
tion (ROM); limited physical activity; and muscle
weakness. It is seen commonly in weight-bearing joints
[e.g., knee osteoarthritis (KOA)].1
Approximately 250 million people worldwide have
KOA.2 In the USA, it is estimated that 80% of the pop-
ulation aged > 65 years may have radiographic KOA,
but only 60% of these subjects may have symptoms.3
The World Health Organization estimated that the in-
cidence of KOA in China in 2009 was 320-340 per
100 000 inhabitants.4 With an aging population, the
challenge facing China will soon become severe.
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The primary aim of KOA management is pain allevia-
tion. Non-steroidal anti-inflammatory drugs
(NSAIDs) are the first-line treatment for KOA, but
can give rise to gastrointestinal bleeding, cardiac risks,
and stroke. Corticosteroids given via the oral route are
not recommended for KOA treatment because of the:
(a) hepatic first-pass effect and (b) high risk of adverse
effects. Increasing the efficacy of drugs is one way to
avoid (or reduce) these adverse effects.
Phonophoresis (also called "sonophoresis") involves the
use of ultrasound to deliver therapeutic compounds
through the skin in a non-traumatic manner. In this
way, the hepatic first-pass effect and side effects of
NSAIDs can be avoided. The NSAID sodium diclofe-
nac (SD) is used for the treatment of acute or chronic
conditions involving pain and inflammation. However,
its application for KOA may be limited in view of its
side effects. According to the literature,5 phonophoresis
using SD is effective for knee-joint pain.6 However,
whether sodium diclofenac phonophoresis (SDP) can
relieve knee-joint stiffness and improve physical func-
tion is not known.
Chinese herbal medicine (CHM) has been used for
thousands of years to treat all types of diseases and dis-
orders, including KOA.7-9 However, the color, appear-
ance, and taste of CHMs are not particularly attractive
for patients. Hence, we screened several CHM prescrip-
tions to find an efficacious recipe and created a gel for-
mulation (Chinese patent number: CN102091158A).
The main ingredients of this CHM prescription were
Guizhi (cassia twig) and cinnamic aldehyde (C9H8O).
Previously, we showed that the amount of cinnamic al-
dehyde that could permeate the skin can be increased
by using a low-frequency ultrasound appliance.10
Whether phonophoresis using this CHM is effective
treatment for KOA and how its effects compare with
those of SDP are not known.
Based on preliminary studies on SDP and the pure in-
gredients used for Chinese herbal medicine phonopho-
resis (CHMP) in KOA treatment in our previous re-
search, we compared the effects of CHMP, SDP, and
phonophoresis using 10% sodium chloride (place-
bo-controlled group (PC) group) for KOA treatment
in terms of improvement of pain, ROM, and the West-
ern Ontario and McMaster Universities Osteoarthritis
Index (WOMACAI).
METHODS
Ethical approval of the study protocol
The study protocol was approved by the Ethics Com-
mittee of the Third Affiliated Hospital of Beijing Uni-
versity of Chinese Medicine (Beijing, China). All pa-
tients provided written informed consent.
Research design
We designed a double-blind, randomized controlled tri-
al. A table of random numbers was generated by a per-
sonal computer. The opaque-envelope method was
used to hide this randomization.
All patients were assigned randomly to the CHMP
group, SDP group, or PC group. Patients underwent
CHMP, SDP, or placebo treatment once a day, five
times a week, for 2 weeks. There was a 4-week fol-
low-up observation after treatment cessation.
Subjects
Patients were recruited from January 2010 to Novem-
ber 2013 from the Third Affiliated Hospital of Beijing
University of Chinese Medicine. All the patients par-
ticipated in this research had signed an informed con-
sent. Ultimately, 100 patients (100 affected knees)
were recruited.
Inclusion criteria
The first set of criteria that patients had to fulfil was
that set by the American College of Rheumatology
for KOA:11 (a) age 40-75 years; (b) symptomatic for ≥
1 month; (c) primary source of pain did not respond
adequately to anti-inflammatory drugs, and the num-
ber of leukocytes in synovial fluid was < 2000/mL; (d)
a minimum score of 2 on a visual analog scale (VAS);
(e) duration of stiffness in the morning ≤ 30 min.
The second set of criteria that patients had to fulfil was
for the diagnosis of blood-stasis syndrome used in tradi-
tional Chinese medicine: (a) "stabbing" pain, and pain
at a fixed location; (b) spotted, blue or purple tongue;
(c) "choppy"pulse.
Exclusion criteria
Patients were excluded if they: (a) had severe disease of
cardio-cerebral blood vessels, liver, kidneys, hematopoi-
etic systems or a psychiatric disease; (b) were allergic to
adhesive plasters, liniments, lotions, or external applica-
tions; (c) had received other therapies that could influ-
ence indices of the effects measured in this study; (d)
were pregnant or lactating; (e) were undergoing gluco-
corticoid treatment < 4 weeks before study enrollment;
(f ) were receiving NSAID treatment < 2 weeks before
study enrollment.
Therapies
Drug phonophoresis was implemented at points (2 cm
in diameter) on the skin of medial and lateral patellar
tendons. Participants were asked to suspend all other
therapies during the trial.
Simultaneous low-frequency phonophoresis (40 kHz,
5000 Pa) was undertaken for 30 min each time.12 For
the CHMP group, the prescription was Guizhi (Ramu-
lus Cinnamomi), Xixin (Herba Asari Mandshurici), Tao-
ren (Semen Persicae), Baishao (Radix Paeoniae Alba),
Huajiao (Pericarpium Zanthoxyli Bungeani), Honghua
(Flos Carthami), Niuxi (Radix Achyranthis Bidentatae),
Caowu (Radix Aconiti Kusnezofii), Ruxiang (Oliba-
num), and Moyao (Myrrh). Each of these drugs (100 g)
was extracted and made into an ointment. Then, the
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ointment was imported into gel chips, with each gel
chip containing 3 mL of the ointment (Chinese patent
number: CN102091158A).
For the SDP group, 10 mg of sodium diclofenac was
contained in each gel chip. For the PC group, each gel
chip contained 3 mL of sodium chloride.
Gel chips used in the three groups were made in China
or by the US Medical Research Institute, and were sim-
ilar in appearance, odor and texture. Personnel in-
volved in the manufacture and packaging of medica-
tions were not allowed to communicate with study par-
ticipants or research personnel.
Measurements
For all subjects, routine blood tests as well as levels of
creatinine, blood urea nitrogen, alanine aminotransfer-
ase and aspartate aminotransferase were recorded be-
fore and after treatment to ensure patient safety. Inves-
tigators recorded adverse events and concomitant use
of medications.
Outcome measurements were recorded 4 weeks after
treatment cessation, and were based on changes in pain
at rest (VAS), pain upon movement (VAS), range of
motion (degrees) and WOMACAI scores.
Statistical analyses
SPSS v17.0 (IBM, Armonk, NY, USA) was used. All
demographic and quantitative data are the mean ±
standard deviation ( xˉ ± s). The Student's t-test was
employed to assess differences between two groups.
The paired t-test was used to assess differences before
and after treatment in the same group. A non-para-
metric test was employed for data with a non-normal
distribution. One-way analysis of variance was used
to assess intergroup differences (CHMP vs SDP vs
PC) in various measurements. P < 0.05 was consid-
ered significant.
RESULTS
Study cohort
The diagram for assignment of randomization is
shown in Figure 1. Four patients dropped out because
follow-up information was not available for them, and
they were excluded from statistical analyses. Hence, 96
patients were evaluated. No adverse events were ob-
served.
Patient characteristics
Baseline characteristics of patients are shown in Table
1. There were no significant differences in age, sex,
BMI, pain duration (months), pain at rest (VAS), pain
upon movement (VAS), ROM (degrees) and WOMA-
CAI scores among groups before treatment (P > 0.05).
Changes in outcome between groups after treatment
Significant differences were found for all outcome mea-
sures after treatment among the three groups (P <
0.05) (Table 2). Intergroup comparison revealed signifi-
cant differences in all outcome measures after treat-
ment except for stiffness and ROM between the
CHMP group and PC group, and between the SDP
group and PC group. No significant differences in all
outcome measures were found after treatment between
the CHMP group and SDP group.
DISCUSSION
We found that CHMP and SDP were effective for
KOA treatment compared with the placebo group.
CHMP and SDP could help relieve pain and improve
physical function significantly. There were no signifi-
cant differences in improvement of stiffness and ROM
Figure 1 Flow diagram for randomized subject assignment
KOA: knee osteoarthritis; CHM: Chinese herbal medicines; SD: sodium diclofenac; PC: placebo controlled.
KOA patients from the
outpatient department who
met theInclusion (n = 100)
Randomization (n = 100)
CHM phonophoresis
(n = 40)
SD phonophoresis
(n = 40) PC group (n = 20)
Result of the clinical trial
(n = 96)
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between the two groups of subjects who received
CHMP or SDP. This is the first double-blind, random-
ized controlled clinical trial designed to evaluate the ef-
ficacy of CHMP in KOA management.
The primary purpose of KOA treatment is to relieve
pain and improve joint function so as to improve quali-
ty of life. Low-frequency phonophoresis can promote
transdermal transport of various drugs, including mac-
romolecules.13 However, not all drugs have increased
permeation if used with ultrasound because of their dif-
ferent physicochemical properties.
The present study suggests that low-frequency phono-
phoresis using CHM and SD is effective for KOA treat-
ment. The primary mechanism of phonophoresis is to
increase skin permeability. Hence, we can infer that
low-frequency phonophoresis can increase transdermal
permeation of a CHM and SD.
Three major factors govern phonophoresis: (a) the
physicochemical properties of the drug formulation;
(b) the ultrasound parameters; (c) skin.14 The ultra-
sound parameters used and the skin condition(all of
the participants had a normal skin and without any
skin disease)in the present study were identical. The on-
ly factor that could have influenced the outcome of
our study was the physicochemical properties of the
drug formulation. There are huge differences in terms
of physical and chemical composition between CHMs
and SD. The latter was a mixture of bioactive com-
pounds, whereas SD is a drug of certain composition.
A possible explanation as to why no differences were
found between subjects who underwent CHMP or
SDP was that although the physicochemical properties
of different drugs may influenced the rate of perme-
ation into skin, there was no difference between the de-
livery speed of a single drug and mixture of drugs.
However, the results of some studies are not in accor-
Table 1 Demographic and baseline characteristics of the patients ( xˉ ± s)
Item
Age (years)
Gender (female/male)
BMI (kg/m2)
Pain duration (months)
Pain at rest (Vas, 0-10)
Pain on movement (Vas, 0-10)
Range of motion (degrees)
WOMAC scores
Total
Pain
Stiffness
Physical function
CHM group (n = 38)
60.3±9.2
(41-70)
31/7
30.6±4.5
(22.7-41.8)
7.5±6.2
(1-35)
5.7±2.4
8.2±2.3
125.0±15.6
11.8±3.7
2.8±1.6
42.3±9.5
56.9±12.3
SD group (n = 39)
59.4±8.9
(44-72)
31/8
31.0±5.2
(22.3-43.7)
6.9±3.9
(1-37)
5.1±2.0
8.6±1.5
124.4±14.5
11.5±3.4
3.1±1.6
42.1±11.6
56.1±14.5
PC group (n = 19)
60.8±9.0
（43-75）
15/4
30.9±4.8
(23.8-44.2)
7.3±5.9
(1-31)
5.6±1.4
8.3±1.9
123.0±15.3
11.7±3.8
2.9±1.7
41.7±10.2
56.4±11.2
P value
0.3
0.4
0.5
0.3
0.8
0.5
0.8
0.9
0.9
0.5
0.6
Notes: CHM group: treated with CHM phonophoresis; SD group: treated with SD phonophoresis; PC group: treated with 10% sodium
chloride phonophoresis. BMI: body mass index; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index (Likert ver-
sion); VAS: visual analog scale (0: no pain, 10: most severe pain); CHM: Chinese herbal medicine; SD: sodium diclofenac; PC: place-
bo-controlled.
Table 2 Changes in clinical outcomemeasures after treatment ( xˉ ± s)
Item
Pain at rest (Vas, 0-10)
Pain on movement (Vas, 0-10)
Range of motion (degrees)
WOMAC scores
Total
Pain
Stiffness
Physical function
CHM Group
(n = 38)
1.42±0.41a
1.22±0.34a
175.00±5.61
2.36±0.79b
2.10±0.20
12.70±2.51b
16.90±3.30b
SD Group
(n = 39)
1.06±0.57a
1.62±0.52a
172.40±4.54
2.09±0.90b
2.10±0.60
13.10±1.61b
17.10±4.51b
PC Group
(n = 19)
5.62±1.41
7.31±0.89
123.80±10.33
9.70±0.50
2.0±0.79
37.70±8.20
48.40±11.20
P value
0.016
0.001
0.062
0.010
0.752
0.013
0.002
Notes: CHM group: treated with CHM phonophoresis; SD group: treated with SD phonophoresis; PC group: treated with 10% sodium
chloride phonophoresis. BMI: body mass index; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index (Likert ver-
sion); VAS: visual analog scale (0: no pain, 10: most severe pain); CHM: Chinese herbal medicine; SD: sodium diclofenac; PC: place-
bo-controlled. Compared with the baseline before treatment among the three groups, aP < 0.01, bP < 0.05.
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dance with those of our study in terms of SD perme-
ation and improvements in stiffness and ROM after
treatment with phonophoresis. Jaqueline et al 15 found
that SD permeation decreased in the presence of ultra-
sound. Falconer et al 16 and colleagues reported a ran-
domized controlled trial in which ultrasound relieved
stiffness and pain for KOA patients with chronic con-
tractures. Possible explanations for the different results
are (a) Jaqueline et al. used pig skin (instead of human
subjects) and ultrasound parameters that differed from
ours and (b) none of our patients had a long-standing
contracture.
This study could provide evidence for clinical treat-
ment of KOA using phonophoresis. A multi-center,
randomized controlled clinical trial is needed for a
more definitive answer on the use of CHMP and SDP
for KOA.
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